X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217776
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761244
https://www.prnewswire.com/news-releases/qilu-pharmaceutical-showcases-ql1706-clinical-trial-outcomes-in-oral-presentation-at-esgo-2024-302090161.html
https://www.prnewswire.com/news-releases/results-from-the-clinical-trial-of-qilu-pharmaceuticals-novel-anticancer-agent-iparomlimab-and-tuvonralimab-ql1706-featured-in-oral-presentation-at-the-esgo-annual-meeting-302078257.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217265
https://www.prnewswire.com/news-releases/results-of-phase-ii-study-on-qilu-pharmaceuticals-novel-drug-ql1706-published-in-signal-transduction-and-targeted-therapy-302051874.html
https://www.prnewswire.com/news-releases/results-of-the-phase-iii-inspire-study-on-qilu-pharmaceuticals-iruplinalkib-published-in-the-journal-of-thoracic-oncology-302047680.html
https://www.prnewswire.com/news-releases/qilu-pharmaceutical-announces-results-from-phase-i-clinical-study-for-its-novel-bispecific-antibody-qls31905-at-esmo-immuno-oncology-congress-302011984.html
https://www.prnewswire.com/news-releases/qilu-pharmaceutical-announces-results-from-phase-ii-study-for-iparomlimab-for-advanced-solid-tumors-at-esmo-asia-with-an-orr-of-45-8-302007254.html
https://www.prnewswire.com/news-releases/phase-i-study-results-for-qilu-pharmaceuticals-iparomlimab-ql1604-now-published-301978372.html
Market Place
Share 
